HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Thodou, E Articles by Pateraki, M Search for Related Content PubMed PubMed Citation Articles by Thodou, E Articles by Pateraki, M Pubmed/NCBI databases Substance via MeSH

Mapping of somatostatin receptor types in GH or/and PRL producing pituitary adenomas

Department of Pathology, G. Gennimatas Athens General Hospital, Athens, Greece

Correspondence to:
Dr G Kontogeorgos Department of Pathology
G. Gennimatas Athens General Hospital, 154 Messogion Avenue, GR-115 27 Athens, Greece; gkonto{at}med.uoa.gr Background: Somatostatin is a tetradecapeptide exerting inhibitory action on endocrine and exocrine cell secretion and proliferation. Somatostatin receptors (SST) are widely expressed in various neoplasms including endocrine tumours. Using immunohistochemistry, the expression of SST₁, SST_2A, SST_2B, SST₃, SST₄, and SST₅ was studied in tissue microarrays (TMAs), using a series of 90 human pituitary adenomas producing growth hormone and/or prolactin, including 30 of each somatotroph, lactotroph, and mixed somatotroph/lactotroph adenoma type.

Methods: For immunohistochemistry, the standard avidin biotin complex method enhanced by tyramide was used, using polyclonal antisera for all SST types. A four point scoring system was used to assess the membranous immunopositivity.

Results: All SST types were positive in all tumour types, showing varying immunoreactivity scores. SST₅ and SST_2A were the predominant receptors, showing strong expression in high frequency in all three adenoma types. Strong expression of SST₁ was higher in lactotroph adenomas than in other tumour types.

Conclusions: The immunohistochemical results of SST expression are in agreement with most findings of previous molecular studies. The fact that SST_2A expression is predominant suggests that pharmaceutical octapeptide somatostatin analogues may act through this receptor, while the role of SST_2B may be merely synergistic.

Abbreviations: GH, growth hormone; PRL, prolactin, SST, somatostatin receptors; TMA, tissue microarray

Keywords: adenomas; immunohistochemistry; pituitary; receptors; somatostatin

This article has been cited by other articles:

				A. Fusco, G. Gunz, P. Jaquet, H. Dufour, A. L. Germanetti, M. D Culler, A. Barlier, and A. Saveanu Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas Eur. J. Endocrinol., May 1, 2008; 158(5): 595 - 603. [Abstract] [Full Text] [PDF]

				U. Plockinger, S. Albrecht, C. Mawrin, W. Saeger, M. Buchfelder, S. Petersenn, and S. Schulz Selective Loss of Somatostatin Receptor 2 in Octreotide-Resistant Growth Hormone-Secreting Adenomas J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1203 - 1210. [Abstract] [Full Text] [PDF]

				A. Ben-Shlomo, O. Pichurin, N. J. Barshop, K. A. Wawrowsky, J. Taylor, M. D. Culler, V. Chesnokova, N.-A. Liu, and S. Melmed Selective Regulation of Somatostatin Receptor Subtype Signaling: Evidence for Constitutive Receptor Activation Mol. Endocrinol., October 1, 2007; 21(10): 2565 - 2578. [Abstract] [Full Text] [PDF]

				D. L. Batista, X. Zhang, R. Gejman, P. J. Ansell, Y. Zhou, S. A. Johnson, B. Swearingen, E. T. Hedley-Whyte, C. A. Stratakis, and A. Klibanski The Effects of SOM230 on Cell Proliferation and Adrenocorticotropin Secretion in Human Corticotroph Pituitary Adenomas J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4482 - 4488. [Abstract] [Full Text] [PDF]